PLX vs. JXN
PLX (Protalix BioTherapeutics, Inc.) and JXN (Jackson Financial Inc.) are both stocks. PLX operates in Biotechnology (Healthcare), while JXN operates in Asset Management (Financial Services). Over the past 3 years, PLX returned 13.29%/yr vs 61.55%/yr for JXN. Their 0.21 correlation means their historical movements had little consistent relationship.
Performance
PLX vs. JXN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PLX achieves a 31.67% return, which is significantly higher than JXN's 16.63% return.
PLX
- 1D
- 4.41%
- 1M
- 2.16%
- 6M
- 1.28%
- YTD
- 31.67%
- 1Y
- 63.45%
- 3Y*
- 13.29%
- 5Y*
- 9.43%
- 10Y*
- -9.60%
- ALL TIME*
- -18.82%
JXN
- 1D
- 0.31%
- 1M
- 17.05%
- 6M
- 4.60%
- YTD
- 16.63%
- 1Y
- 50.40%
- 3Y*
- 61.55%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 44.81%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $65.15M | $73.11M | $71.41M | |
| $1.21M | $1.29M | $1.54M |
PLX vs. JXN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
PLX Protalix BioTherapeutics, Inc. | 31.67% | -4.26% | 5.62% | 29.93% | 64.72% | -49.29% |
JXN Jackson Financial Inc. | 16.63% | 26.93% | 76.45% | 57.22% | -11.54% | 69.65% |
Correlation
The correlation between PLX and JXN is 0.11, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.11 |
Correlation (3Y) Balances recent behavior with more history. | 0.21 |
Correlation (All Time) Calculated using the full available price history since Sep 1, 2021 | 0.21 |
Fundamentals
PLX:
$190.95M
JXN:
$8.53B
PLX:
$0.19
JXN:
-$8.20
PLX:
2.51
JXN:
0.98
PLX:
$76.38M
JXN:
$5.86B
PLX:
$53.44M
JXN:
$5.39B
PLX:
$20.91M
JXN:
-$22.00M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PLX vs. JXN — Risk / Return Rank
PLX
JXN
PLX vs. JXN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Protalix BioTherapeutics, Inc. (PLX) and Jackson Financial Inc. (JXN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PLX | JXN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.38 | ||
| Sortino ratioReturn per unit of downside risk | -0.29 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 1.24 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | 1.58 | 2.73 | -1.16 |
| Martin ratioReturn relative to average drawdown | 2.63 | 5.77 | -3.14 |
Loading charts...
Drawdowns
PLX vs. JXN - Drawdown Comparison
The maximum PLX drawdown since its inception was -99.91%, which is greater than JXN's maximum drawdown of -48.34%. Use the drawdown chart below to compare losses from any high point for PLX and JXN.
Loading charts...
Drawdown Indicators
| PLX | JXN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.91% | -48.34% | -51.57% |
Max Drawdown (1Y)Largest decline over 1 year | -39.68% | -16.31% | -23.37% |
Max Drawdown (3Y)Largest decline over 3 years | -56.03% | -37.09% | -18.94% |
Max Drawdown (5Y)Largest decline over 5 years | -73.21% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -94.38% | — | — |
Current DrawdownCurrent decline from peak | -99.73% | -2.72% | -97.01% |
Average DrawdownAverage peak-to-trough decline | -93.68% | -14.84% | -78.84% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.74% | 7.72% | +16.02% |
Volatility
PLX vs. JXN - Volatility Comparison
The current volatility for Protalix BioTherapeutics, Inc. (PLX) is 9.46%, while Jackson Financial Inc. (JXN) has a volatility of 11.26%. This indicates that PLX experiences smaller price fluctuations and is considered to be less risky than JXN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PLX | JXN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.46% | 11.26% | -1.80% |
Volatility (6M)Calculated over the trailing 6-month period | 43.33% | 25.03% | +18.30% |
Volatility (1Y)Calculated over the trailing 1-year period | 63.83% | 32.83% | +31.00% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 67.42% | 45.24% | +22.18% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 79.18% | 45.24% | +33.94% |
Dividends
PLX vs. JXN - Dividend Comparison
PLX has not paid dividends to shareholders, while JXN's dividend yield for the trailing twelve months is around 2.78%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
JXN Jackson Financial Inc. | 2.78% | 3.00% | 3.22% | 4.84% | 6.32% | 1.20% |
PLX Protalix BioTherapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
PLX vs. JXN - Financials Comparison
This section allows you to compare key financial metrics between Protalix BioTherapeutics, Inc. and Jackson Financial Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
PLX vs. JXN - Profitability Comparison
PLX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Protalix BioTherapeutics, Inc. reported a gross profit of 29.62M and revenue of 33.75M. Therefore, the gross margin over that period was 87.8%.
JXN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Jackson Financial Inc. reported a gross profit of 0.00 and revenue of 2.90B. Therefore, the gross margin over that period was 0.0%.
PLX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Protalix BioTherapeutics, Inc. reported an operating income of 21.15M and revenue of 33.75M, resulting in an operating margin of 62.7%.
JXN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Jackson Financial Inc. reported an operating income of 0.00 and revenue of 2.90B, resulting in an operating margin of 0.0%.
PLX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Protalix BioTherapeutics, Inc. reported a net income of 18.32M and revenue of 33.75M, resulting in a net margin of 54.3%.
JXN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Jackson Financial Inc. reported a net income of -435.00M and revenue of 2.90B, resulting in a net margin of -15.0%.
Frequently Asked Questions
PLX and JXN have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
JXN has higher volatility (11.26%) compared to PLX (9.46%). In terms of maximum drawdown, PLX dropped -99.91% vs JXN's -48.34%.
JXN currently has the higher Sharpe Ratio (1.36 vs 0.98), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PLX and JXN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer